GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bacil Pharma Ltd (BOM:524516) » Definitions » Equity-to-Asset

Bacil Pharma (BOM:524516) Equity-to-Asset : 0.92 (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Bacil Pharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bacil Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹12.13 Mil. Bacil Pharma's Total Assets for the quarter that ended in Mar. 2024 was ₹13.26 Mil.

The historical rank and industry rank for Bacil Pharma's Equity-to-Asset or its related term are showing as below:

BOM:524516' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34   Med: 0.93   Max: 0.98
Current: 0.92

During the past 13 years, the highest Equity to Asset Ratio of Bacil Pharma was 0.98. The lowest was 0.34. And the median was 0.93.

BOM:524516's Equity-to-Asset is ranked better than
95.58% of 1086 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs BOM:524516: 0.92

Bacil Pharma Equity-to-Asset Historical Data

The historical data trend for Bacil Pharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bacil Pharma Equity-to-Asset Chart

Bacil Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.34 0.34 0.96 0.98 0.92

Bacil Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 - 0.97 - 0.92

Competitive Comparison of Bacil Pharma's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Bacil Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bacil Pharma's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bacil Pharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Bacil Pharma's Equity-to-Asset falls into.



Bacil Pharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Bacil Pharma's Equity to Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Equity to Asset (A: Mar. 2024 )=Total Stockholders Equity/Total Assets
=12.131/13.261
=

Bacil Pharma's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=12.131/13.261
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bacil Pharma  (BOM:524516) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Bacil Pharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Bacil Pharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Bacil Pharma (BOM:524516) Business Description

Traded in Other Exchanges
N/A
Address
Sir P. M. Road, No. 71, Laxmi Building, 4th Floor, Fort, Mumbai, MH, IND, 400 001
Bacil Pharma Ltd is an Indian-based pharmaceutical company operating in a single segment. It is engaged in the manufacturing of pharmaceuticals, medicinal chemicals, and botanical products. The company manufactures, exports, supplies, and retail Anti Anxiety Medicine, Antihistamines, Chemical Compound, Drugs and Herbal Tablets, and Capsules.

Bacil Pharma (BOM:524516) Headlines

No Headlines